Association of neutrophil to eosinophil ratio (NER) with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line (1L) immune checkpoint inhibitors (ICI) -based regimens.

被引：0
|
作者：
Eid, Marc
Labaki, Chris
Semaan, Karl
Saliby, Renee Maria
Saad, Eddy
Shah, Valisha
Choueiri, Toni K.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4557
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Baseline neutrophil-to-eosinophil ratio (NER) and its association with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI).
    Ravindranathan, Deepak
    Liu, Yuan
    Martini, Dylan J.
    Brown, Jacqueline T.
    Nazha, Bassel
    Russler, Greta
    Yantorni, Lauren Beth
    Caulfield, Sarah
    Carthon, Bradley Curtis
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
    Zhuang, Tony Z.
    Ravindranathan, Deepak
    Liu, Yuan
    Martini, Dylan J.
    Brown, Jacqueline T.
    Nazha, Bassel
    Russler, Greta
    Yantorni, Lauren B.
    Caulfield, Sarah
    Carthon, Bradley C.
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    [J]. ONCOLOGIST, 2022, : 239 - 245
  • [3] BODY COMPOSITION MAY BE PROGNOSTIC AND PREDICTIVE OF CLINICAL OUTCOMES IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICI)
    Martini, Dylan
    Olsen, T. Anders
    Goyal, Subir
    Liu, Yuan
    Evans, Sean
    Magod, Benjamin
    Brown, Jacqueline
    Yantorni, Lauren
    Russler, Greta
    Caulfield, Sarah
    Goldman, Jamie
    Nazha, Bassel
    Harris, Wayne
    Kucuk, Omer
    Carthon, Bradley
    Master, Viraj
    Bilen, Mehmet
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A26 - A27
  • [4] Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens
    Saad, Eddy
    Gebrael, Georges
    Semaan, Karl
    Eid, Marc
    Saliby, Renee Maria
    Labaki, Chris
    Sayegh, Nicolas
    Wells, J. Connor
    Takemura, Kosuke
    Ernst, Matthew Scott
    Lemelin, Audreylie
    Basappa, Naveen S.
    Wood, Lori A.
    Powles, Thomas
    Ernst, D. Scott
    Lalani, Aly-Khan A.
    Agarwal, Neeraj
    Xie, Wanling
    Heng, Daniel Y. C.
    Choueiri, Toni K.
    [J]. ONCOLOGIST, 2024, 29 (08): : 699 - 706
  • [5] Primary resistance (PrR) versus acquired resistance (AcR) to immune checkpoint inhibitors (ICI) in first-line metastatic renal cell carcinoma (mRCC)
    Guida, A.
    Silva, C. Alves Costa
    Colomba-Blameble, E.
    Flippot, R.
    Salviat, F.
    Bracarda, S.
    Escudier, B.
    Albiges, L.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S570 - S570
  • [6] Association between circulating cytokines expression patterns and outcomes to immune-checkpoint (ICI)-based regimens in metastatic renal cell carcinoma (mRCC)
    Linville, Laura Meili
    Feinaj, Ardit
    Nathani, Kaizen
    Singla, Nirmish
    Yarchoan, Mark
    Markowski, Mark Christopher
    Carducci, Michael Anthony
    Munjal, Kabeer
    Thoburn, Christopher
    Gizzi, Jennifer
    Kao, Chester
    Elias, Roy
    Ged, Yasser
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Impact of renin-angiotensin system inhibitors (RASi) on outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI)
    Nuzzo, P. V.
    Adib, E.
    Weise, N.
    Curran, C.
    Stewart, T.
    Freeman, D.
    Nassar, A. H.
    Abou Alaiwi, S.
    Bakouny, Z.
    McGregor, B. A.
    Choueiri, T. K.
    Jain, R. K.
    Mckay, R. R.
    Sonpavde, G. P.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S702 - S703
  • [8] Efficacy of first-line immune checkpoint inhibitors in patients with sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).
    Bakouny, Ziad
    Abou Alaiwi, Sarah
    Nassar, Amin
    Steinharter, John A.
    Wei, Xiao X.
    McGregor, Bradley Alexander
    Harshman, Lauren Christine
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [9] yyEfficacy of immune-checkpoint inhibitor (ICI) combination as a first-line (1L) therapy in metastatic renal cell carcinoma (mRCC) with sarcomatoid histology: A systematic review and meta-analysis.
    Siddiqi, Rabbia
    Kumar, Gaurav
    Ijaz, Hafsah
    Naqvi, Syed Arsalan Ahmed
    Ayaz, Ahsan
    Bin Riaz, Zaryab
    Bryce, Alan Haruo
    Ho, Thai Huu
    Bin Riaz, Irbaz
    Singh, Parminder
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [10] Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
    Martini, Dylan J.
    Liu, Yuan
    Shabto, Julie M.
    Carthon, Bradley Curtis
    Russler, Greta
    Hitron, Elise
    Caulfield, Sarah
    Kissick, Haydn
    Harris, Wayne
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345